Moreover, improvement or maintenance of HRQoL is consistently observed for enzalutamide across the prostate cancer spectrum, as well as for other therapies such as abiraterone acetate (in mCSPC and mCRPC), darolutamide (in nmCRPC) and apalutamide (in nmCRPC and mCSPC), indicating that this class of androgen receptor-targeted therapies may be a good choice for qualifying patients with prostate cancer [24,25,26,27,28,29,30]. Here, AR is linked to prostate carcinoma.